Web20 gen 2024 · 196 Background: The phase III trial (JCOG1104), comparing between 4- (6 months) and 8-course (1 year) of S-1 as the adjuvant chemotherapy for pathological … Web6 set 2024 · For example, JCOG1104 categorized into low risk group is the phase III study which compares 6-months versus 3-months of adjuvant S-1 chemotherapy for pathological stage II gastric cancer patients who undergo D2 gastrectomy. This study does not include investigational surgery arm, ...

Efficacy of Postoperative Chemotherapy After Resection that

Web3 set 2024 · Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2024;4(3):208–16. Article Google Scholar Web1 mar 2024 · We report the primary results of a phase 3, open-label, multicentre, randomised controlled trial—the JCOG1104 (optimal period of adjuvant chemotherapy S-1 [OPAS-1] study)—to assess the non-inferiority of four courses of S-1 (corresponding to 6 months) compared with eight courses of S-1 (corresponding to 1 year) for patients with … implante conus hi

Facilitated completion of 1-year adjuvant S-1 monotherapy for ...

WebThe primary results of JCOG1104, a phase-III study to confirm the non-inferiority of 4-course S-1 to 8-course S-1 as adjuvant chemotherapy for stage-II gastric cancer, was published in the Gastroenterology and Hepatology section of The Lancet. Web18 gen 2024 · Log in. Sign up Web1 mar 2024 · JCOG1104 (OPAS-1), an open-label, phase III, non-inferiority, randomized trial, showed that for patients with stage II GC, 4 cycles of S-1 were inferior to 8 cycles of … implantech associates